Multimodal Glioma Immunotherapy Combining TLR9-Targeted STAT3 Antisense Oligodeoxynucleotides with PD1 Immune Checkpoint Blockade

Scientists suggested rationale for the glioblastoma immunotherapy using CpG-STAT3dsASO to disrupt GAMs-dependent immune evasion, thereby restoring sensitivity to PD1-blockade and facilitating T cell-mediated antitumor immune responses.